Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen, a biotechnology company, has announced the distribution of newly designated Series C Preferred Stock to holders of its common stock. Each outstanding share of common stock will receive one one-thousandth of a share of Series C Preferred Stock. The Series C Preferred Stock will vote together with the common stock on certain proposals and will have 1,000,000 votes per share. Shares not present at the shareholders meeting will be automatically redeemed with no voting power. The Series C Preferred Stock will be uncertificated and non-transferable except in connection with a transfer of common stock.
Ocugen, Inc. announced that its senior executives will present at two investor conferences in May 2024, highlighting the Company's gene and cell therapy clinical development progress, including the OCU400 Phase 3 clinical trial for retinitis pigmentosa. Dr. Shankar Musunuri and Dr. Huma Qamar will participate in the events.
Ocugen, Inc. will host a conference call on May 14, 2024, to discuss first quarter 2024 financial results and business updates. The company is focused on gene and cell therapies and vaccines. Attendees can join via dial-in numbers or webcast. A replay will be available on the investor site.
Ocugen, a biotechnology company, announced Dr. Arun Upadhyay, CSO, will present at the Retina World Congress on modifier gene therapy. The company's abstract on gene therapy for retinitis pigmentosa has been accepted. Their Phase 3 clinical trial for OCU400 is progressing towards BLA and MAA approval by 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.